As a result of the current global COVID-19 public health crisis, interest in and awareness of relevant clinical research has emerged as a path to access new and innovative treatments. TransCelerate is equipped to raise clinical trial awareness and access and help facilitate an increase in focus on the inclusion of the patient experience throughout
Welcome to TransCelerate
TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high-quality delivery of new medicines.
TransCelerate Launches New Initiatives to Support COVID-19 Research, R&D of Medicines, & More
DataCelerate® COVID-19 Module, Modernizing Critical Trial Conduct, Real World Data and Pharmacovigilance Agreements Optimization were all launched to support the continuity of clinical trials. We’ve also elected new Board leaders and added Bayer Pharmaceuticals as our newest member.
TransCelerate has been actively monitoring the evolving COVID-19 crisis and we are providing our Member Companies a trusted and collaborative forum to discuss the ongoing disruption to drug development. TransCelerate Member Companies are using this informal forum to voluntarily discuss best practices and various options for addressing multiple drug development matters as the situation evolves.
Beyond COVID-19: Modernizing Clinical Trial Conduct
The COVID-19 pandemic required swift implementation of innovative solutions to protect participant safety and enable clinical trial continuity. The pandemic catalyzed the expansion and acceleration of existing continuity solutions as well as the establishment of new ones. These continuity solutions should be extended beyond the pandemic to retain the benefits for participants and modernize clinical trials. This new white paper describes the broad categories of continuity solutions utilized, the challenges related to their use, and the factors that made implementation successful.
TransCelerate Expands COVID-19 Clinical Trial Data Sharing to Non-Member Companies
TransCelerate is expanding access to COVID-19-related patient-level clinical data sharing via DataCelerate® to non-member companies. In addition, TransCelerate will expand the type of data shared to include data from both the investigational product and control arms of COVID-19 clinical trials.
TransCelerate Launches New Blog: Accelerate to Innovate
We have created a new blog—Accelerate to Innovate—to improve public understanding of the life sciences industry and to provide our audience with more information on how our new and existing solutions can boost the resiliency of the R&D process during these difficult times.
GCP Mutual Recognition
The TransCelerate Site Qualification and Training (SQT) Initiative has developed a Mutual Recognition (MR) Program for ICH E6 Good Clinical Practice (GCP) Training, targeted to investigator site personnel. Our GCP Mutual Recognition program was created to reduce redundant training and hours spent by investigators who need to complete the same training if they work with multiple sponsors.
TransCelerate Member Companies have translated select solutions for potential use within the broader global community. Current translations include solutions concerning Common Protocol Template, Site Qualification & Training, Quality Management Systems and Patient Experience.
- Welcome to TransCelerate
- TransCelerate Launches New Initiatives to Support COVID-19 Research, R&D of Medicines, & More
- COVID-19 Response
- Beyond COVID-19: Modernizing Clinical Trial Conduct
- TransCelerate Expands COVID-19 Clinical Trial Data Sharing to Non-Member Companies
- TransCelerate Launches New Blog: Accelerate to Innovate
- GCP Mutual Recognition
- Translated Solutions